Pharmaceuticals and biotechnology companies have been in the global focus more than usual of late, with researchers worldwide looking to develop solutions for the recent Ebola outbreak in Africa. Investors have been active all along, however, with nearly 60 PE deals in the space this year, on pace for 77. As PE in general looks to recover from a somewhat less active 3Q, a strong fourth quarter for biopharma could result in the industry group's biggest year post-crisis, according to the PitchBook Platform.
In particular, if 4Q can match the 26 deals from the same quarter in 2013, it would just eclipse last year's total, which at 83 was the second-highest since 2007. Almost 450 investors have backed biopharma companies in the past decade; some of the most active in the past two years have been Ardian Private Equity and Avista Capital Partners—four deals apiece. Roundtable Healthcare Partners has made 13 investments since the start of 2005.
Click here for a closer look at PE activity in biopharma.